First Citizens Bank & Trust Co. decreased its stake in Johnson & Johnson (NYSE:JNJ) by 12.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 77,217 shares of the company’s stock after selling 11,022 shares during the quarter. Johnson & Johnson makes up about 1.5% of First Citizens Bank & Trust Co.’s holdings, making the stock its 9th biggest position. First Citizens Bank & Trust Co.’s holdings in Johnson & Johnson were worth $10,788,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Harding Loevner LP bought a new position in shares of Johnson & Johnson during the 2nd quarter valued at $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its holdings in shares of Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares in the last quarter. Mountain Capital Investment Advisors Inc bought a new position in shares of Johnson & Johnson during the 2nd quarter valued at $124,000. Lenox Wealth Management Inc. raised its holdings in shares of Johnson & Johnson by 1.7% during the 2nd quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock valued at $193,000 after purchasing an additional 24 shares in the last quarter. Finally, Intercontinental Wealth Advisors LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter valued at $200,000. Institutional investors own 67.21% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of Johnson & Johnson stock opened at $131.19 on Thursday. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.51. The stock has a market cap of $352,023.59, a price-to-earnings ratio of 17.97, a price-to-earnings-growth ratio of 2.09 and a beta of 0.77. Johnson & Johnson has a 12-month low of $120.95 and a 12-month high of $148.32.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.02. The company had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The business’s quarterly revenue was up 11.5% on a year-over-year basis. During the same period last year, the business posted $1.58 EPS. sell-side analysts predict that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th were given a $0.84 dividend. The ex-dividend date of this dividend was Monday, February 26th. This represents a $3.36 annualized dividend and a yield of 2.56%. Johnson & Johnson’s dividend payout ratio is 861.54%.

In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the sale, the vice president now directly owns 357,906 shares in the company, valued at approximately $46,477,673.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.19% of the company’s stock.

A number of research analysts have recently weighed in on the stock. Citigroup cut their price target on shares of Johnson & Johnson from $150.00 to $146.00 and set a “neutral” rating on the stock in a report on Tuesday, February 27th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price on the stock in a report on Thursday, January 11th. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a report on Wednesday, January 24th. Finally, Jefferies Group set a $165.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, February 26th. Four equities research analysts have rated the stock with a sell rating, nine have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $146.26.

COPYRIGHT VIOLATION NOTICE: “First Citizens Bank & Trust Co. Has $10.79 Million Holdings in Johnson & Johnson (JNJ)” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/first-citizens-bank-trust-co-has-10-79-million-holdings-in-johnson-johnson-jnj/1955954.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.